Verastem Inc (VSTM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.03B
Last updated: Nov 17, 2026 at 11:05 AM ET
Verastem Inc (VSTM) Stock Forecast
Analysts expect Verastem (VSTM) to earn -$1.90 per share in the fiscal year ending Dec 31, 2026, on revenue of $107.72M. Of 10 analysts, 10 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 1.90, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 10.0% |
| Buy | 9 | 90.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 34.3%.
- Fiscal year ending Dec 31, 2026
- -$1.90
- EPS consensus, revenue $107.72M
- Fiscal year ending Dec 31, 2027
- -$1.55
- EPS consensus, revenue $144.62M
- Next report
- Mar 2, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.90 | -$1.90 to -$1.90 | 1 | $107.72M | $94.29M to $111.58M | 8 |
| Dec 31, 2027 | -$1.55 | -$1.55 to -$1.55 | 1 | $144.62M | $115.70M to $184.00M | 9 |
Quarterly Estimates
The EPS consensus rises from -$0.50 for the quarter ending Dec 31, 2026 to -$0.43 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.50 | -$0.70 to -$0.36 | 12 | $27.36M | $24.60M to $30.26M | 11 |
| Mar 31, 2027 | -$0.43 | -$0.43 to -$0.43 | 1 | $27.63M | $24.50M to $30.49M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.80.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.90 | -$1.80 | -$1.80 | -$1.80 | -$1.80 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.55 | -$1.22 | -$0.75 | -$0.75 | -$0.75 | N/A |
Frequently Asked Questions About VSTM
What is the VSTM stock forecast?
Consensus analyst estimates put Verastem's EPS at -$1.90 for the fiscal year ending Dec 31, 2026, on revenue of $107.72M. The consensus rating from 10 analysts is Buy.
How do analysts rate VSTM stock?
Of 10 analysts covering Verastem, 1 rates it Strong Buy, 9 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from VSTM next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.90, with estimates from -$1.90 to -$1.90 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.55, with estimates from -$1.55 to -$1.55 from 1 analyst.
What revenue do analysts expect from Verastem next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $107.72M, with estimates from $94.29M to $111.58M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $144.62M, with estimates from $115.70M to $184.00M.
How many analysts cover VSTM?
10 analysts rate Verastem stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
VSTM pages: Overview, Earnings, Forecast, Financials, Competitors